This study employed the ANRGs signature risk score to classify breast cancer patients into high- and low-risk groups, enabling the identification of noticeable differences in immune cell infiltration, particularly CD8 T cells, between these subgroups. The gene discussed is CD8A; the disease is breast carcinoma.